C Diff Drug Development

An experimental vaccine failed to prevent Clostridioides difficile infection in a phase 3 trial but successfully reduced the duration of symptoms, infections requiring medical attention and antibiotic treatments, researchers reported.

Crestone’s novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for Clostridioides difficile infection.

The small-molecule protein synthesis inhibitor CRS3121 met its primary endpoints, with high rates of clinical cure at day 12 and low rates of CDI recurrence.

Polyphenols have been reported to inhibit C. difficile growth and toxin production by several mechanisms in preclinical studies. However, more clinical studies are needed to investigate their safety in humans.

BOULDER, Colo.--(BUSINESS WIRE)--Sep 5, 2024--

CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.

Key Points

Polyphenols have been reported to inhibit C. difficile growth and toxin production by several mechanisms in preclinical studies. However, more clinical studies are needed to investigate their safety in humans.

Proactive's Tylah Tully breaks down 'Just the Facts' of Immuron Ltd (NASDAQ:IMRN, ASX:IMC)'s (Immuron Ltd (NASDAQ:IMRN, ASX:IMC)) lastest ASX announcement....

The potential role of nemonoxacin, which can be administered parenterally, for treating CDIs was evidenced through the in vitro, ex vivo, and mouse models.

our results showed that HXZQ can protect mice from CDAD-related death as effectively as vancomycin and the combination of vancomycin and HXZQ may give even better protection.

It's time to look at oral vaccines to prevent C. difficile infections, experts say

Three PF-06425090 doses were safe and well-tolerated. Although the primary endpoint was not met, PF-06425090 reduced symptom duration, CDI requiring medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden. NCT03090191.

The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.

Nestlé aims to increase the global availability of Vowst, an FDA-approved therapy for preventing recurrent C difficile infection, while also seeking new opportunities for the product worldwide.

The vaccine didn't reduce C difficile infections in at-risk adults, but it did show the potential to reduce infection severity and limit need for medical attention.

Three PF-06425090 doses were safe and well-tolerated. Although the primary endpoint was not met, PF-06425090 reduced symptom duration, CDI requiring medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden. NCT03090191.

The study is registered at ClinicalTrials.gov (NCT03931941).

The end of toxoid vaccine development for preventing Clostridioides difficile infections?

Antimicrobial resistance poses a significant threat to humanity, and the development of new antibiotics is urgently needed. Our research has focused on thiopeptide antibiotics such as micrococcin P2 (MP2) and derivatives thereof as new anti-infective agents. Thiopeptides are sulfur-rich, structurall …

Due to envelope differences between Gram-positive and Gram-negative bacteria, engineering precision bactericidal contractile nanomachines requires atomic-level understanding of their structures; however, only those killing Gram-negative bacteria are currently known. Here, we report the atomic struct …

ABSTRACT Clostridium difficile is the primary cause of nosocomial antibiotic-associated diarrhea in the Western world. The major virulence factors of C. difficile are two exotoxins, toxin A (TcdA) and toxin B (TcdB), which cause extensive colonic ...

Current treatment of clostridial infections includes broad-spectrum antibiotics and antitoxins, yet antitoxins are ineffective against all Clostridiumspecies. Moreover, rising antimicrobial resistance (AMR) threatens treatment effectiveness and public health. This study therefore aimed to dis …

The synthesized recombinant proteins were capable of inducing antibody titers against C. difficile toxins A and B in sows, and were passively transferred to piglets through colostrum.

/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today...

Lumen scientists were the first to crack that long-standing barrier. Once that was done, we started looking around for useful applications. To our surprise, we discovered that there is actually a very robust literature on orally delivered therapeutic proteins, although most people are unaware of it.

Development of novel antibacterial agents is imperative due to the increasing threat of antibioticresistant pathogens. This study aimed to develope the enhanced antibacterial activity and in-vivo efficacy of a novel truncated endolysin, CHAPSAP26-161, derived from the endolysin LysSAP26, …

Acurx Pharmaceuticals announced that results from the ibezapolstat Phase 2 clinical trial in patients with C. difficile Infection, or CDI, were presented at the 17t...